Posted by Martin June 23, 2024

Bristol Myers Squibb Co (BMY) is facing significant challenges, should you invest?

Bristol Myers Squibb Co (BMY) has long been a stalwart in the pharmaceutical industry, renowned for its innovative therapies and robust product pipeline. However, the company is facing a significant challenge with a projected 92% drop in operating earnings for 2024, primarily due to expiring patents on key drugs. This blog post aims to provide Continue reading →